Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report published on Tuesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Up 1.7 %

TTNP opened at $7.09 on Tuesday. Titan Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $16.60. The firm has a 50-day moving average price of $7.36 and a two-hundred day moving average price of $7.16. The stock has a market capitalization of $6.45 million, a PE ratio of -0.86 and a beta of 1.33.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.